Ofer Margalit
Overview
Explore the profile of Ofer Margalit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Margalit O, Stemmer A, Chapin W, Shacham-Shmueli E, Kopetz S, Andre T, et al.
Eur J Cancer
. 2024 Sep;
212:114336.
PMID: 39316932
Background: Immune checkpoint blockade (ICB) has revolutionized treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). However, there is no evidence on the optimal treatment duration. We aimed...
2.
Lawrence Y, Miszczyk M, Dawson L, Diaz Pardo D, Aguiar A, Limon D, et al.
Lancet Oncol
. 2024 Jul;
25(8):1070-1079.
PMID: 39029483
Background: Refractory upper abdominal pain or lower back pain (retroperitoneal pain syndrome) related to celiac plexus involvement characterises pancreatic and other upper gastrointestinal malignancies and is an unmet need. We...
3.
Ben-Yaacov A, Elbaz N, Schtrechman G, Adileh M, Levine O, Goldstein A, et al.
Am Surg
. 2024 May;
90(11):2876-2884.
PMID: 38810100
Background: Inflammatory bowel diseases (IBDs) pose an increased risk of gastrointestinal cancer with especially worse prognosis. Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) improves outcomes in selected patients with colorectal...
4.
Stemmer A, Margalit O, Serpas V, Strauss G, Thomas J, Shah P, et al.
Eur J Cancer
. 2023 Dec;
198:113495.
PMID: 38157568
Background: This study aims to assess predictive markers for response to immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) patients. Materials And Methods: A study using two prospective cohorts from MD...
5.
Halpern N, Boursi B, Shacham-Shmueli E, Nili Gal-Yam E, Margalit O, Golan T, et al.
Oncol Ther
. 2023 Oct;
11(4):513-519.
PMID: 37864026
Introduction: It is unclear how soon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection it is safe to resume systemic anti-neoplastic treatment in patients with cancer. We assessed the...
6.
Margalit O, Harmsen W, Shacham-Shmueli E, Voss M, Boursi B, Wagner A, et al.
Eur J Cancer
. 2023 Oct;
194:113339.
PMID: 37813779
No abstract available.
7.
Margalit O, Shacham-Shmueli E, Strauss G, Yang Y, Lawrence Y, Ben Nun A, et al.
Cancer Invest
. 2023 Sep;
41(8):734-738.
PMID: 37665657
Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged...
8.
Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, et al.
Clin Colorectal Cancer
. 2023 Sep;
22(4):442-449.e1.
PMID: 37657954
Introduction: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. We hypothesized that a combination of intratumoral TLR9 agonist, radiosurgery and dual PD-1 and CTLA-4...
9.
Margalit O, Harmsen W, Shacham-Shmueli E, Voss M, Boursi B, Wagner A, et al.
Eur J Cancer
. 2022 Nov;
178:162-170.
PMID: 36446161
Background: Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant. Methods: Data...
10.
Mor E, Assaf D, Laks S, Gilat E, Hazzan D, Shacham-Shmueli E, et al.
J Gastrointest Surg
. 2022 Nov;
27(1):131-140.
PMID: 36327025
Background: Constraints of pelvic anatomy render complete cytoreduction (CRS) challenging. The aim of this study is to investigate the impact of pelvic peritonectomy during CRS/HIPEC on colorectal peritoneal metastasis (CRPM)...